Cystic fibrosis (CF) patients who monitored their lung function at home using NuvoAir‘s handheld spirometer and smartphone app were able to better engage in telemedicine, a U.K. survey found, with these patients reporting a more than 30% drop in their number of scheduled and urgent in-person consultations. The study based…
News
NHS England and Vertex Pharmaceuticals have reached an agreement that will allow access to Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), a triple combination therapy for cystic fibrosis (CF) to be used in a combination regimen with Kalydeco, as soon as the medication is approved by the European…
Anxiety related to fears of COVID-19 infection was higher among mothers of children with cystic fibrosis (CF) than those of healthy children, although teenage patients themselves were less anxious than age-matched peers without CF, a survey of families in Turkey reported. Mothers of young patients with chronic lung infections, and…
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and…
Nontuberculous mycobacteria (NTM), a type of infectious bacteria, is able to survive being dried for a full day, a study found, suggesting that drying is not a sufficient way to disinfect nebulizers used by people with cystic fibrosis (CF). The study, “Susceptibility of the Mycobacterium…
A potential way of killing persistent bacterial infections like those common to people with cystic fibrosis (CF) — using nutrient channels that may exist within bacterial communities to carry antibiotics — is suggested by a research team at the University of Strathclyde in Glasgow. Their study, “…
AR-501, an inhaled treatment candidate for chronic lung infections in people with cystic fibrosis (CF), has been deemed safe and well-tolerated in healthy volunteers, results from the first part of a Phase 1/2a clinical trial show. The trial’s safety monitoring committee (SMC) and a data safety monitoring board…
Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants. “Patient and laboratory studies have…
Eloxx Pharmaceuticals has resumed enrollment in its Phase 2 clinical trial evaluating ELX-02 in cystic fibrosis (CF) patients in Israel and Europe, after it was temporarily halted due to the COVID-19 pandemic. “We are pleased that enrollment in our Phase 2 clinical…
After being given more than $3 million from the Cystic Fibrosis Foundation (CFF) in 2017 to expand the development of viral vectors for gene delivery in the lungs, 4D Molecular Therapeutics (4DMT) now will receive up to $14 million from CFF to support the development of a…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.